Mustang Bio, Inc. Non-operating Interest Expenses

Non-operating Interest Expenses of MBIO for past 10 years: annual, quarterly and twelve month trailing (TTM) including Non-operating Interest Expenses growth rates and interactive chart. Interest expense that is usually non-recurring and not tied to a company's operations. It is stated separately on the income statement to differentiate it from interest expenses.


Highlights and Quick Summary

  • Non-operating Interest Expenses for the quarter ending September 29, 2021 was $75 Thousand (a -11.76% decrease compared to previous quarter)
  • Year-over-year quarterly Non-operating Interest Expenses decreased by -46.81%
  • Annual Non-operating Interest Expenses for 2020 was $708 Thousand (a -43.94% decrease from previous year)
  • Annual Non-operating Interest Expenses for 2019 was $1.26 Million (a 121.97% increase from previous year)
  • Annual Non-operating Interest Expenses for 2018 was $569 Thousand (a 12.67% increase from previous year)
  • Twelve month Non-operating Interest Expenses ending September 29, 2021 was $435 Thousand (a -16.67% decrease compared to previous quarter)
  • Twelve month trailing Non-operating Interest Expenses decreased by -58.37% year-over-year
Trailing Non-operating Interest Expenses for the last four month:
29 Sep '21 29 Jun '21 30 Mar '21 30 Dec '20
$435 Thousand $522 Thousand $579 Thousand $1.05 Million
Visit stockrow.com/MBIO for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Non-operating Interest Expenses of Mustang Bio, Inc.

Most recent Non-operating Interest Expensesof MBIO including historical data for past 10 years.

Interactive Chart of Non-operating Interest Expenses of Mustang Bio, Inc.

Mustang Bio, Inc. Non-operating Interest Expenses for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2021 $0.08 $0.09 $0.13
2020 $0.14 $0.16 $0.14 $0.6 $0.71
2019 $0.6 $0.58 $0.57 $0.01 $1.26
2018 $0.57
2017 $0.01 $0.0 $0.51
2016 $0.95 $0.2 $0.02
2015 $0.06 $0.0

Business Profile of Mustang Bio, Inc.

Sector: Healthcare
Industry: Biotechnology
Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline focuses on gene therapy programs for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors. The company develops MB-107 and MB-207, a gene therapy program for X-linked severe combined immunodeficiency, a rare genetic immune system condition in which affected patients do not live beyond infancy without treatment. The company also develops MB-102 CAR T therapies for blastic plasmacytoid dendritic cell neoplasm, acute myeloid leukemia, and myelodysplastic syndrome; MB-106 CAR T cell program for B cell non-hodgkin lymphoma and chronic lymphocytic leukemia; MB-104 CAR T for multiple myeloma and light chain amyloidosis; MB-101 CAR T cell program for glioblastoma; MB-103 CAR T for glioblastoma multiforme (GBM) and metastatic breast cancer to brain; MB-105 CAR T for prostate and pancreatic cancers; and MB-108, a next-generation oncolytic herpes simplex virus. It has license agreements with Nationwide Children's Hospital, SIRION Biotech GmbH, and Minaris Regenerative Medicine GmbH. The company was incorporated in 2015 and is headquartered in Worcester, Massachusetts.